HCV Treatment
All-Oral Regimens -- The Future of Hepatitis C Treatment
- Details
- Category: HCV Treatment
- Published on Tuesday, 08 November 2011 00:00
- Written by Liz Highleyman
Attendees at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) this week in San Francisco got a glimpse of the future of chronic hepatitis C therapy, as several researchers presented data from studies of all-oral direct-acting antiviral (DAA) regimens -- without interferon and its notoriously difficult side effects.
NEJM: High SVR Rate with Daclatasvir + Asunaprevir
AASLD: Daclatasvir + Asunaprevir Suppresses HCV in Null Responders
AASLD: PSI-7977 + Ribavirin Cures Hepatitis C in 12 Weeks
AASLD: BI 201355 + BI 201127 + Ribavirin Looks Good in SOUND-C
AASLD 2011: Daclatasvir plus Asunaprevir Rapidly Suppresses HCV in Prior Null Responders
- Details
- Category: HCV Treatment
- Published on Tuesday, 08 November 2011 00:00
- Written by Liz Highleyman
A dual antiviral regimen containing the novel hepatitis C virus (HCV) NS5A inhibitor daclatasvir (BMS-790052) plus the NS3 protease inhibitor asunaprevir (BMS-650032) -- without interferon -- produced rapid and sustained viral suppression in Japanese prior null responders with HCV genotype 1b, researchers reported at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) this week in San Francisco.
Pharmasset Starts Phase 3 Trials of PSI-7977 Without Interferon
- Details
- Category: HCV Treatment
- Published on Friday, 04 November 2011 00:00
- Written by Pharmasset
Pharmasset, Inc. announced this week that it has begun a Phase 3 program of studies of its hepatitis C virus (HCV) polymerase inhibitor PSI-7977 taken once-daily in combination with ribavirin but not pegylated interferon. These trials will enroll previously untreated people with HCV genotype 2 or 3, and patients with any genotype who cannot use interferon.
AASLD 2011: PSI-7977 plus Ribavirin Can Cure Hepatitis C in 12 Weeks without Interferon
- Details
- Category: HCV Treatment
- Published on Tuesday, 08 November 2011 00:00
- Written by Liz Highleyman
An all-oral dual regimen containing Pharmasset's hepatitis C virus (HCV) polymerase inhibitor PSI-7977 plus ribavirin produced 100% sustained response at 12 weeks in previously untreated people with HCV genotypes 2 or 3, according to findings from the ELECTRON study reported at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) this week in San Francisco.
Achillion Finds Promising New HCV NS5A Inhibitor Candidate
- Details
- Category: HCV Treatment
- Published on Tuesday, 01 November 2011 00:00
- Written by Achillion Pharmaceuticals
Achillion Pharmaceuticals recently announced that it has selected a second-generation hepatitis C virus (HCV) NS5A inhibitor for development, designated ACH-3102. NS5A inhibitors are among the direct-acting antiviral agents that have begun to revolutionize hepatitis C treatment. The function of the HCV NS5A protein is not fully understood, but it appears to both play a role in viral replication and influence host response.
More Articles...
- Vertex to Test 12-Week Telaprevir for People with Favorable IL28B Gene Pattern
- HCV Polymerase Inhibitor Setrobuvir Looks Safe and Effective in Interim Analysis
- EACS 2011: Predictors of HCV Viral Load in HIV/HCV Coinfected Patients
- IDSA 2011: Boceprevir Increases Hepatitis C Treatment Response for HIV/HCV Coinfected People
Web Design and Development by